Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to evaluate the effect of Prostaglandin I2 analogue use on the development of chronic allograft nephropathy and changes in allograft function in prevalent renal transplant recipients
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
prevalent renal transplant recipients 2 years after transplantation
no history of acute rejection
stable renal function
history of biopsy-proven chronic allograft nephropathy
history of biopsy-proven CNI nephrotoxicity
history of biopsy-proven or clinical acute rejection
unstable trough level of CNI or extremely low level of CNI